Phoxim Veterinary Grade API is the non-salt organothiophosphate active substance used in solid and liquid veterinary preparations for the control of susceptible ectoparasites in cattle, sheep, swine, and poultry. The crystalline active substance is chemically defined as (E)-N-(diethoxyphosphinothioyloxy)benzenecarboximidoyl cyanide, identified by CAS 14816-18-3, molecular formula C12H15N2O3PS, and molecular weight 298.3 g/mol. The standard veterinary-grade model is a purified, low-residue powder with a minimum assay of 98.0% on the dried basis; it is not a finished dosage form and requires formulation-specific manufacturing controls before use in tablets, injections, capsules, powders, granules, premix, or solutions.

Unlike technical-grade phoxim used in agricultural insecticide applications, the veterinary-grade API is manufactured under ICH Q7 GMP conditions, with defined residual solvent removal, impurity reporting, change control, and batch documentation. Technical-grade material may contain higher levels of process impurities and is not supported by veterinary drug master files; therefore it is unsuitable for pharmaceutical compounding or licensed veterinary medicines.

Phoxim Veterinary Grade API Identity and Compendial Alignment

Release specifications combine orthogonal identification by infrared absorption and HPLC retention time against a qualified reference standard. The melting range observed by capillary method or differential scanning calorimetry is ordinarily 103–107 °C. Loss on drying is controlled at not more than 0.5% after 2 h at 60 °C under vacuum, and water content by Karl Fischer is maintained at not more than 0.5%. Sulfated ash is limited to 0.1% maximum, and heavy metals are controlled at not more than 10 ppm. Related substances are evaluated by HPLC; a single unspecified impurity is limited to 0.10% and total impurities to 0.5% under ICH Q3A thresholds applicable to a maximum daily dose below 2 g/day. Residual solvents are assigned according to ICH Q3C: Class 1 solvents are excluded or maintained below general limits, and Class 2 solvents are held within Option 2 limits.

For tablets and capsules, the choice between direct compression and wet granulation is determined principally by phoxim particle size distribution, cohesiveness, and dose strength. Low-dose tablets containing 10–50 mg of phoxim per unit often require wet granulation to achieve content uniformity under Ph. Eur. 2.9.40 or USP ⟨905⟩; direct compression may be acceptable when the API is micronized or co-processed with a flowable diluent such as spray-dried lactose monohydrate. On rotary tablet presses operating above 50,000 tablets/h, variation in API D90 beyond the qualified range is observed as weight control drift and hardness fluctuation. Powder flow for capsule hoppers is commonly controlled to a Carr index below 25 and a Hausner ratio below 1.25 using Ph. Eur. 2.9.36 or USP ⟨1174⟩. Dry granulation is less suited when the API level exceeds 30% w/w because compacted ribbons can become sticky and prone to screen blinding.

How Does Low Aqueous Solubility Constrain Injectable and Solution Formulations?

For injectable solutions and oral drenches, phoxim requires non-aqueous or co-solvent vehicles because the crystalline API has low water solubility. Propylene glycol, ethanol, dimethylacetamide, or benzyl alcohol-containing vehicles are selected according to the target animal and route of administration. The active substance is susceptible to hydrolytic degradation at alkaline pH; therefore aqueous diluents or buffered solutions are adjusted to pH 4.0–6.5 and stored in tightly sealed type I glass or lined closures to limit water ingress. Terminal steam sterilization is generally unsuitable for phoxim-containing solutions because organothiophosphate hydrolysis accelerates with heat and water activity; aseptic filtration or dry-heat-compatible non-aqueous systems may be required. Filtration through a 0.22 µm membrane after dissolution reduces particulate burden, with clarity evaluated according to Ph. Eur. 2.9.20 and sub-visible particle counts according to Ph. Eur. 2.9.19 or USP ⟨788⟩.

Premix and granule manufacturing stations require explicit carrier selection and dust containment because low-dose premixes may contain 0.1–5.0% w/w phoxim on carriers such as lactose monohydrate, corn cob meal, or precipitated silica. Sequential geometric dilution is required; batch records should document mixer load, rpm, and blending time because homogeneity under production-scale ribbon mixers is sensitive to carrier particle size distribution and electrostatic charge. Dust suppression is addressed by adding light mineral oil or vegetable oil at 0.5–1.0% w/w. Cleaning validation for contact surfaces uses a risk-based limit derived from the permitted daily exposure; swab analytical methods should achieve a limit of quantification not higher than half the acceptance value. Rework should not be performed without stability assessment because repeated blending and storage can increase fines and moisture uptake.

If Oxon Impurity Control Is Required, Closed Milling and Drying Atmospheres Become Specifications

The veterinary-grade API is specified not only by assay but by the related substances profile. The oxon analogue, generated by oxidative desulfuration, is of particular concern because it is a more active acetylcholinesterase inhibitor than the parent thioate. HPLC methods capable of resolving the oxon analogue from phoxim are used; a method detection limit at or below 0.05% is normally required. Production-scale milling and drying can increase oxon content if the API is exposed to hot, moist air or to residues of hydrogen peroxide from equipment cleaning. Closed milling circuits with nitrogen blanketing have been used to limit oxidative impurity formation during size reduction for direct compression batches. Packaging in sealed, light-resistant containers with desiccant is recommended when the API is stored in climates where ambient relative humidity exceeds 60%.

Regulatory and Chemical Differences from Technical-Grade Phoxim and Other Organophosphates

Compared with technical-grade phoxim, the veterinary-grade material is differentiated by GMP status, lower related substances, residual solvent control, and particle size consistency. It is also not interchangeable with other organophosphate veterinary APIs. Phoxim has molecular weight 298.3 g/mol and melting range 103–107 °C; diazinon has molecular weight 304.35 g/mol and is a liquid at room temperature, while coumaphos has molecular weight 362.77 g/mol and a higher melting point. Formulation of phoxim into solid dosage forms therefore requires different solvent and drying conditions than diazinon-based liquid pour-ons or coumaphos-based acaricidal dip concentrates. The lower residue catalogue of the veterinary-grade model also simplifies justification of analytical method specificity when multiple actives are evaluated in the same dosage form.

Storage and handling boundaries include protection from light, maintenance of tightly closed containers at controlled room temperature, and separation from strong oxidizers, alkaline materials, and open sources of moisture. Formulators should not incorporate phoxim into aqueous vehicles above neutral pH without supporting forced degradation data, and should qualify all contact surfaces for washability because the active substance can adhere to stainless steel and polymer transfer lines after solvent evaporation.